Iveric's Zimura Succeeds In Dry AMD Study
Stock Sees Three-Day Gain Of 283%
The New York-headquartered firm, which recently decided to focus on gene therapy, has to decide whether to partner Zimura or go it alone.
The New York-headquartered firm, which recently decided to focus on gene therapy, has to decide whether to partner Zimura or go it alone.